Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panel

View ORCID ProfileSangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park, Jaemo Koo, Hansol Park, Joonoh Lim, Erin Connolly-Strong, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn, Hyun Woo Lee, Seokhwi Kim, Jang-Hee Kim, View ORCID ProfileMinsuk Kwon
doi: https://doi.org/10.1101/2023.12.20.23300156
Sangmoon Lee
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sangmoon Lee
Jin Roh
2Department of Pathology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Sung Park
3Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Islam Oguz Tuncay
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wonchul Lee
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jung-Ah Kim
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Baek-Lok Oh
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jong-Yeon Shin
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeong Seok Lee
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young Seok Ju
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryul Kim
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seongyeol Park
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaemo Koo
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hansol Park
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joonoh Lim
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Connolly-Strong
1Genome Insight Inc., San Diego. CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tae-Hwan Kim
4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Won Choi
4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mi Sun Ahn
4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyun Woo Lee
4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seokhwi Kim
2Department of Pathology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jang-Hee Kim
2Department of Pathology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minsuk Kwon
4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Minsuk Kwon
  • For correspondence: mskwon{at}ajou.ac.kr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Cancer poses a significant global health challenge, with increasing incidence rates demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial cancer alterations. Whole-genome sequencing (WGS) addresses this gap, offering extensive genomic testing. This study demonstrates the potential medical application of WGS.

Methods This study evaluates the power of target-enhanced WGS (TE-WGS), a clinical-grade WGS method sequencing both cancer and matched normal tissues. A cohort of forty-nine patients with various solid cancer types underwent both TE-WGS and TruSight Oncology 500 (TSO500), one of the mainstream TPS approaches currently used in the clinic.

Results TE-WGS methods detected all the variants reported from TSO500 (100%, 498/498). A high correlation in the detection of variant allele fractions (VAF) was observed between the TE-WGS and TSO500 methodologies (r=0.977). Notably, within the pool of 498 variants commonly detected by both approaches, 223 variants (44.8%) were discerned within peripheral blood samples exclusively through the TE-WGS technique, suggesting their presence as constitutional variants inherent to the germline. Conversely, the remaining subset of 275 variants (55.2%) were not detected in peripheral blood using the TE-WGS method, signifying them as bona fide somatic variants. Further, TE-WGS provided accurate copy number profiles, fusion-genes, MSI- and homologous-recombination deficiency (HRD) scores, which were essential for clinical decision making.

Conclusion TE-WGS proves to be a comprehensive approach in personalized oncology, matching the key biomarker detection capabilities of the established TSO500 panel. Additionally, TE-WGS uniquely identifies germline variants and genomic instability markers, offering additional clinical actions. Its adaptability and cost-effectiveness further underscore its clinical utility, making TE-WGS a valuable tool in personalized cancer treatment.

Competing Interest Statement

M.K. currently holds a consultancy/advisory role for MSD and Genome Insight Inc., and M.K. has received grant/research funding from Genome Insight Inc. These affiliations may present potential conflicts of interest related to the submitted manuscript.

Funding Statement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2022R1F1A1074910). This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C1734, HI23C1589).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board of Ajou University Hospital (AJOUIRB-SMP-2022-271)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 21, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panel
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panel
Sangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park, Jaemo Koo, Hansol Park, Joonoh Lim, Erin Connolly-Strong, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn, Hyun Woo Lee, Seokhwi Kim, Jang-Hee Kim, Minsuk Kwon
medRxiv 2023.12.20.23300156; doi: https://doi.org/10.1101/2023.12.20.23300156
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panel
Sangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park, Jaemo Koo, Hansol Park, Joonoh Lim, Erin Connolly-Strong, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn, Hyun Woo Lee, Seokhwi Kim, Jang-Hee Kim, Minsuk Kwon
medRxiv 2023.12.20.23300156; doi: https://doi.org/10.1101/2023.12.20.23300156

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3284)
  • Dentistry and Oral Medicine (362)
  • Dermatology (275)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1166)
  • Epidemiology (13346)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5137)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (428)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14615)
  • Intensive Care and Critical Care Medicine (911)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4907)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4196)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (203)